从天然生物活性生物相容聚合物制成胰岛素的新药输送系统的配方
Howida A Fetouh1, Engy E A Aleem2, Najiyah H Mohammed2
1Chemistry Department, Faculty of Science, Alexandria University, Alexandria, Egypt. howida_fetouh@alexu.edu.eg.
Scientific reports
|January 31, 2025
概括
使用基和瓜尔的新型胰岛素药物递送系统显示出可控释放的前景. 这些系统保护胃中的胰岛素,并在肠道和血液中有效释放胰岛素.
科学领域:
- 生物材料科学 生物材料科学
- 药物输送系统 药物输送系统
- 聚合物化学 聚合物化学
背景情况:
- 开发有效的胰岛素药物输送系统 (IDD) 对糖尿病管理至关重要.
- 现有的系统面临着稳定性,受控释放和生理兼容性的挑战.
研究的目的:
- 开发和描述使用天然聚合物的新型胰岛素载体:基和基移植的瓜尔 (基-g-GG).
- 在模拟生理条件下评估这些新的IDDs的体外释放动力学和稳定性.
主要方法:
- 修改的sol-gel方法用于制备insulin@chitin和insulin@chitin-g-GG.
- 在37°C的体外胰岛素释放研究中,通过pH范围 (1.2,6.8,7.4) 模拟胃,肠,结肠和血液.
- 使用伪二阶模型分析释放动力学.
- 用于稳定性评估的泽塔潜力测量.
主要成果:
- 胰岛素@胆仅在pH7.4时才显示释放,这表明在较低的pH值时具有强烈的结合.
- 胰岛素@胆-g-GG表现出持续和向性胰岛素释放,释放率在pH值6.8>7.4>1.2之后.
- 释放动力学遵循伪二阶模型,表明异质的表面相互作用.
- 这两种系统都显示出负泽塔潜力,确保了体稳定性.
- 瓜尔的结合改善了颗粒大小分布和胰岛素释放特征.
结论:
- 开发的insulin@chitin-g-GG系统为持续和有针对性的胰岛素输送提供了一个有希望的方法.
- 该系统提供对酸性胃状况的保护,并在肠道和血液环境中控制释放.
- 结果突出了天然聚合物,如素和瓜尔在先进的药物输送应用中的潜力.
相关概念视频
Insulin Formulations: Types and Delivery
162
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
162
Insulin: Biosynthesis, Chemistry, and Preparation
346
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
346
Biopharmaceutics and Pharmacokinetics: Overview
1.8K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
1.8K
Drug Delivery: Overview
274
The selection of a drug's delivery route depends upon its physicochemical properties, including lipid or water solubility and ionization, as well as the therapeutic requirement, such as immediate or sustained effect. These routes can be divided into three primary categories: enteral, parenteral, and topical.
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the...
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the...
274
Factors Influencing Drug Absorption: Pharmaceutical Parameters
113
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
113
Glucagon-like Receptor Agonists
292
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
292


